{"id":"https://genegraph.clinicalgenome.org/r/0e387047-20f9-4ccd-bb02-94953bb207b0v1.0","type":"EvidenceStrengthAssertion","dc:description":"Lafora disease (LD) is a fatal autosomal recessive form of adolescent-onset neurodegenerative disease, charaterized by progressive myoclonus epilepsy and neurodeterioration. The hallmark of the disease is presence of periodic acid-Schiff-positive polyglucosan inclusion bodies, called Lafora bodies. Mainly two genes, EPM2A and NHLRC1, have been associated with LD. LD was first reported to be associated with EPM2A in 1998 in a study that identified seven EPM2A variants in ten families (Minassian et al. 1998. PMID: 9771710). Since then, 32 deletions/insertions/frameshifts, 13 nonsense, and 57 missense variants have been identified in LD patients according to the Lafora Progressive Myoclonus Epilepsy Mutation and Polymorphism Database (http://projects.tcag.ca/lafora/). Nineteen symptomatic probands from 19 families with homozygous or compound heterozygous EPM2A variants studied by six studies were scored for genetic evidence (PMID: 9771710, 9931343, 11175283, 12019207, 12560877, 14722920). While many of the variants were unique to each family, one variant, c. 721C>T; p.Arg241* in NM_005670.3, has a relatively high occurrence due to both founder effect and recurrence verified by a haplotype study (11175283). Nine probands had two variants in trans that were not predicted/proven to be null, and were given scores ranging from 0 to 1. The remaining ten probands had at least one of the two variants in trans that were proven/predicted to be null, and were given scores ranging from 1 to 2. Functional studies rather than presence of Lafora bodies were used to upgrade the points for some studies (9771710, 9931343, 11175283, 12560877), because presence of Lafora bodies were documented only as a study inclusion statement in the methods section, and/or only EPM2A was studied. No LOD scores could be calculated from these families, because only single affected individual was reported for each case. Supporting experimental evidence includes expression (11355878), protein interaction (15930137), non-human model organism (12019206), and rescue in non-human model organism (24430976). In summary, a score of 12 was given to genetic evidence, and 4 to experimental evidence, reaching 16 in total. EPM2Aâ€™s association with LD is upgraded from strong to definitive, because it has been replicated for more than 2 decades.","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/0e387047-20f9-4ccd-bb02-94953bb207b0","GCISnapshot":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10005","date":"2020-05-23T19:00:00.000Z","role":"Approver"}],"curationReasonDescription":"","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bab491bb-63c4-4381-8347-cb324236904f","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0fd25621-0d03-4fca-bcec-5ff09647ad99","type":"Finding","dc:description":"Presence of spontaeneous myoclonic epilepsy, Lafora bodies in both brain and liver, neurodegeneration, behavioral deterioration apparent in progressive ataxia, muscle weakness, and startle responses that do not habituate, as well as deficit in retention of passive avoidance of electric shock.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12019206","rdfs:label":"EPM2A knock-out mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/335c42a1-bef5-43ac-b231-aaf7c52a6b67","type":"EvidenceLine","dc:description":"Only Lafora bodies were observed. They did not make a control line overexpressing WT EPM2A. No seizures or neurodegeneration was observed. There is another paper using the same phosphatase-dead laforin, but this paper showed that the p.C266S laforin can rescue the knockout mouse's Lafora bodies (24430976). So, it is not clear whether the p.C266S laforin expression leads to Lafora body formation. it is not clear whether p.C266S laforin can sequester substrate, or phosphatase activity is important for the EPM2A pathophysiology.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/65c37934-cc56-4dbe-95a7-0b0e6944e78b","type":"Finding","dc:description":"They both accumulated lafora bodies in the brain, heart, liver, and muscles.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15102711","rdfs:label":"Phosphatase dead laforin overexpression mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f42e04c8-a7d1-48cc-b3ac-a9d10dfc0e0e","type":"EvidenceLine","dc:description":"No seizure phenotypes were studied. The memory test was not statistically significant. Give 0.5 points for the rescue of Lafora bodies.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3fecc247-b971-4ea3-a379-8ff91ab21cd6","type":"Finding","dc:description":"Lafora bodies in the hippocampus, cerebellum, and the heart were rescued at 3 months, 7-10 months and 12 months by WT and phosphatase-dead laforin transgenes. The LC3-II protein which is associated with autophagosomes was used to detect autophagosomes. reduced autophagosomes in kncoout mice were rescued  in the mouse as well as the embryonic fibrablasts derived from the mouse lines. The memory test by object recognition seemed to show rescues, but it was not statistically significant. They did not test the seizure phenotypes.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24430976","rdfs:label":"EPM2A knockout rescue by WT and phosphatase-dead laforin","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityNonHumanRescueCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f1482949-0e60-4d97-a780-914e867e2382","type":"EvidenceLine","dc:description":"Variant level evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/89dfef35-5b17-4412-a9b6-a7b5fa9778f6","type":"FunctionalAlteration","dc:description":"WT Laforin was evenly distributed in the cytoplasm, but variant Laforin either made aggregates (T194I, G279S, Y294N) or localized to nuclei as well as cytoplasm (W32G, R108C), or was not detectable (S25P). Two variants did not change subbcellular localization of Laforin (E28L, F88L).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12019207","rdfs:label":"Subcellular localization"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/5c6f41a0-e0bc-480c-af8b-bbaabab58995","type":"EvidenceLine","dc:description":"Variant level functional evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3ed7eb05-dde7-4014-a57d-0c536a7aaf18","type":"FunctionalAlteration","dc:description":"The Flag tagged Laforin was expressed in HEK 293 cells and immunoprecipitated by anti-FLAG beads, and the phosphatase activity toward pNPP was assayed. All the variants reduced Laforin's phosphatase activity was 50% of wild type Laforin.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11739371","rdfs:label":"Phosphatase activity of Laforin"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2dad5bfb-2239-491a-8463-85489ca253ff","type":"EvidenceLine","dc:description":"Variant level evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c7f2b02f-a9ba-472b-949d-02b7305fce06","type":"FunctionalAlteration","dc:description":"Lafora disease variants were introduced to EPM2A genes by in vitro mutagenesis, and was expressed in HEK293 and NIH3T3 cells. The variant Laforin levels were reduced compared to WT Laforin. They also tested the expression level under Cycloheximide (protein synthesis inhibitor) and Actinmycin D (RNA synthesis inhibitor). Cyclohexamide caused reduction in the variant protein, but Actinomycin D had very little effects, suggesting that the protein level i regulated at protein level rather than transcription level. Then they found out that this apparent reduction in protein level was due to aggregation of variant Laforin rendering them insoluble. By Western blotting by anti-ubiquitin, they found that Laforin aggregates are polyubiquitinated. They confirmed this by co-expressing variant Laforin with HA-ubiquitin, and immunoprecipitating by anti-V5 or anti-Myc, the tags fused to Laforin constructs. Then the immunoprecipitates were detected in Western blots by anti-HA. Then they also did immunohistochemistry using anti-V5 on HEK293 cells and Neuro2A cells transfected by V5-Laforin variants. They found aggregated immunoreactivity in cells transfected by disease variant-laforin, but not WT Laforin. These aggregates were stained by antibodies against 20S proteasome, vimentin, and ubiquitin.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19403557","rdfs:label":"aggregation and ubiquitination of variant Laforin"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1b747803-506d-497a-afd8-b410d2030af6","type":"EvidenceLine","dc:description":"Variant level functional evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/59fe89c2-8b4b-42b5-945e-65921f642b58","type":"FunctionalAlteration","dc:description":"The purified Laforin was tested for phosphatase activity using paranitrophenyl-phosphate (pNPP) as a substrate. The phosphatase activity was reduced in the variant Laforin compared to the wild type Laforin.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14722920","rdfs:label":"Phosphatase activity of Laforin"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/8496d310-df0b-4196-a1da-af4eee908de8","type":"EvidenceLine","dc:description":"Variant-level functional evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd40bec6-2a08-4617-a439-b51de46fc91f","type":"FunctionalAlteration","dc:description":"The myc/his tagged laf331 with the laf331-specific variants were co-expressed in COS 7 cells together with FLAG-tagged laf331 or laf317, and pulled down using Ni-resin and detected in tag-specific antibody. The laf331, but not laf317, was pulled-down by Q319fs and L310W mutants, suggesting that these mutations have abolished the interaction between laf331 and laf317.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/18617530","rdfs:label":"dimerization of Laforin isoforms"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/0206e79a-133e-4604-9fde-54ce6ab4704b","type":"EvidenceLine","dc:description":"This will be used as variant-level evidence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f01ae96-de4b-4498-85c3-199025093950","type":"FunctionalAlteration","dc:description":"GST Laforin fusion protein was bacterially expressed, and its tyrosine phosphatase activity was studied with a synthetic substrate, OMFP.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001928","rdfs:label":"Phosphatase activity"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/18932d3b-915a-495f-8572-4ec25969dbdf","type":"EvidenceLine","dc:description":"Variant level functional evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e35ffb59-a2ea-4bbf-a2a7-818275d9f88e","type":"FunctionalAlteration","dc:description":"The Flag tagged Laforin was expressed in HEK 293 cells and the cell lysates were incubated with in the presence or absence of alpha-amylase. Then cell lysates were subjected to ultracentrifugation (100,000g) for 90 min and pellet and supernatant were subjected to Western blot by anti-FLAG antibody. Wild type and p.Cys266Ser Laforin were detected in pellet (glycogen microsomes) as well as supernatant in the absence of alpha-amylase, whereas they were present exclusively in the supernatant in the presence of alpha-amylase. The p.Trp32Gly, p.Lys87ALa, and double-variant Laforins were always detected in the supernatant, suggesting that they disrupt Laforin's ability to bind glycogen. They also tested glycogen binding using bacterially expressed recombinant purified His-tagged Laforin for WT, p.Cys266Ser, and Double-variant p.Trp32Gly and p.Lys87ALa, by incubating them with glycogen and ultracentrifugation. WT and p.Cys266Ser were found in the pellet whereas the double-variant Laforin was found in supernatant.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11739371","rdfs:label":"Glycogen binding"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/bdd95f08-6591-4049-acdb-ea3bb5aba9c2","type":"EvidenceLine","dc:description":"Variant level ecidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/741ad060-fa55-42fe-b3d0-3d3503ef0447","type":"FunctionalAlteration","dc:description":"Lafora disease -associated variants, p.Trp32Gly, p.Phe84Leu, p.Arg108Cys, p.Thr194Ile, p.Gly240Ser, p.Arg241*, p.Gly279Ser, p.Gln293Leu, p.Tyr294Asn, and p.Pro301Leu were tested. With the exception of p.Gly240Ser, all the variants caused reduction of phosphatase activity. \np.Arg241* (CA314500), p.Gly279Ser (CA252542), p.Tyr294Asn (CA366190097), and p.Pro301Leu (CA314505) could not be added below.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14532330","rdfs:label":"Fernandez-SanchezFig1C"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/35a5ed11-127d-4022-bd66-4e07c9310e89","type":"EvidenceLine","dc:description":"Variant level functional evidence","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4af04598-1a58-4476-93b5-b1edb8df92f7","type":"FunctionalAlteration","dc:description":"Laforin protein was not detectable in either patient samples even in the presence of proteasome inhibitor MG132. RNA expression measured by real-time qPCR was reduced to ~40% of WT in patient cell p.Arg241*/p.Arg241* and ~70% in patient cell p.Tyr112*/p.Asn163Asp.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30041081","rdfs:label":"Laforin expression in patient-derived fibroblasts"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/0bca1cf4-e3d0-46c2-bde9-6e3a3b83b88f","type":"EvidenceLine","dc:description":"Variant level evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/17f631db-af87-47c6-8f07-74301365c396","type":"FunctionalAlteration","dc:description":"Phosphatase activity against glycogen of purified wild type and variant Laforin was measured by a system that utilizes malachite green to detect inorganic phosphate. Result showed that all the variant Laforins had reduced phosphatase activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25544560","rdfs:label":"Phosphatase activity of Laforin with variants in active site"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/41764891-2b8b-488f-9af2-2e7f17c7b542","type":"EvidenceLine","dc:description":"This is variant level evidence.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/94096c45-ca17-4a70-90ba-c2e5c60e8cf6","type":"FunctionalAlteration","dc:description":"But the mutant proteins were seen as aggregates and colocalized weakly with lysosomal marker cathepsin D. All aggregates were ubiquitin positive.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11001928","rdfs:label":"Ganesh2000Fig9"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/3c7d5b5f-27b4-42d6-9eea-48fa12f134e1","type":"EvidenceLine","dc:description":"Variant level functional evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/083b0dd6-e1cf-463a-b2f4-d6e6bce7b92a","type":"FunctionalAlteration","dc:description":"WT as well as p.Cys266Ser and p.Asp234Ala laforin-EGFP were localized in a punctate pattern whereas p.Trp32Gly, p.Lys87ALa, and double-variant Laforins were evenly distributed in the COS 1 cell.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11739371","rdfs:label":"Subcellular localization of Laforin"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/06fbe01f-b77b-4bf7-ae97-4a1c61ed01c4","type":"EvidenceLine","dc:description":"Variant level evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6048f46c-0dbf-485a-8e7a-85f205b0f1e1","type":"FunctionalAlteration","dc:description":"Among variants tested, only p.Trp32Gly, p.Lys87Ala, and p.Trp99Ala reduced glycogen binding.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25544560","rdfs:label":"Glycogen binding"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/0a4a0845-5b25-4843-83a6-4c81f869856d","type":"EvidenceLine","dc:description":"Variant level evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5005aeb8-4b90-4a86-8086-9cc6ac3c0490","type":"FunctionalAlteration","dc:description":"All the variants except for p.Gly240Ser had reduced glycogen binding.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14532330","rdfs:label":"Fernandez-SanchezFig1D"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/8339703a-1879-4458-b6b9-7b14ac18ac99","type":"EvidenceLine","dc:description":"Variant level evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e58ff69-271a-4367-8633-2f3174a771ca","type":"FunctionalAlteration","dc:description":"Only p.Arg108Cys and p.Thr194Ile reduced the interaction with laforin itself. All the variants reduced the interaction with PPP1R3C","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14532330","rdfs:label":"Fernandez-SanchezFig5"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/28b1214e-bf4d-4f49-b585-9ec74629fb08","type":"EvidenceLine","dc:description":"Although this seems to be a ubiquitously expressed gene, they also found that the mRNA expression increases postnatally, and peaks at 160 day, which corresponds to adulthood in rat. This fits with age of onset of Lafora disease. They also performed a in situ hybridization on rat brain, detecting highest expression in hippocampus and cerebellum, and moderate expression in cerebral cortex, olfactory bulb, striatum, and thalamus, confirming expression in the relevant brain regions.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/341b2b2f-fb06-488a-912d-aa6ccf8b947e","type":"Finding","dc:description":"Expression of rat EPM2A mRNA was detected in above tissues from rat by Northern blot by EMP2A cDNA clone. \nThe mRNA expression in the brain increases postnatally, and peaks at 160 day, which corresponds to adulthood in rat. This fits with age of onset of Lafora disease. They also performed a in situ hybridization on rat brain, detecting highest expression in hippocampus and cerebellum, and moderate expression in cerebral cortex, olfactory bulb, striatum, and thalamus, confirming expression in the relevant brain regions.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11355878","rdfs:label":"Northern Blot and In situ hybridization","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/654802d2-e040-437c-834a-6305f9008147","type":"EvidenceLine","dc:description":"Although they claim that the transcript was detected in all the tissues tested, the bands were invisible for many of the tissues.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97f94370-fbbd-40b3-afdf-bb3fa6d5fd7e","type":"Finding","dc:description":"Northern blot for human adult tissues was performed using a probe against human EPM2A. They claim that the transcript was detected in all tissues tested, the bands were invisible except for the colon and skeletal muscle.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9931343","rdfs:label":"Northern blot on human adult tissues","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/29d463c0-ab80-48a9-87f9-329fe2c4f16b","type":"EvidenceLine","dc:description":"Although the result seems consistent with the rest of the paper showing laforin is associated with lafora bodies, no proper negative control was done on the anti-human laforin antibody which had been unsuccessful in detecting native laforin in healthy individuals. Furthermore, the patient has a NHLRC1 variant, and therefore, it is not clear whether we can use this evidence for the curation of EPM2A-Lafora disease association","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d2175ffc-4a43-49cc-b7a1-c17ffd5c9e89","type":"Finding","dc:description":"Antibodies to human laforin could not detect native laforin in healthy individuals; however, immunoreactivity was detected at lafora bodies of brain biopsy samples from a lafora disease patient with a homozygous NHLRC1 variant. This suggests that laforin is physically associated with lafora bodies. The result is consistent with the rest of this paper showing that overexpressed phosphatase-dead laforin in the transgenic mouse was physically associated with polyglucosan in lafora bodies.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15102711","rdfs:label":"Human laforin binding to lafora bodies","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/62f902d2-071f-4dee-a1fe-767b1c040686","type":"EvidenceLine","dc:description":"This is only used as a variant level evidence","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/50d6ca14-3e16-49a3-9443-9b97204512d2","type":"Finding","dc:description":"Laforin's binding to Lafora bodies and glycogen is suggestive of its role in  formation and/or clearance of the hallmark of this disease.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14706656","rdfs:label":"Laforin binding to Lafora bodies","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/3f710715-cd53-4f80-a48d-e2a2efb0dcaf","type":"EvidenceLine","dc:description":"Although they claimed ubiquitous expression, some bands are invisible on the picture.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/06c5bc21-466c-45eb-bbea-d6628a04a6c6","type":"Finding","dc:description":"They did a Northern blot of human tissues using probes against human EPM2A. They claim in the text that they found a 3.2 kbp transcript in all tissue tested (including heart, brain, liver, and skeletal muscle). However, the band in liver is very weak on the picture, and it is not clear whether the signal is a leakage from Skeletal muscle or a true signal. The brain signal is also weak, although they found positive signals in many brain areas.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","rdfs:label":"Northern blot of human tissues","demonstrates":{"id":"cg:GeneExpressionA"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/d86dc759-18a5-45a0-af76-36cb1a36425a","type":"EvidenceLine","dc:description":"Increased glycogen synthase and its increased activity in the EPM2A and NHLRC1 knockout mice may not cause Lafora body formation as has been shown in Tiberia et al. 2012 PMID: 22669944","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7f30d77e-9e68-4655-b829-d6edc2fa3a2a","type":"Finding","dc:description":"Lafora bodies, inclusion bodies present in several tissues as as the brain, liver, muscle, and the skin are the hallmark of this disease.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17952067","rdfs:label":"Laforin/Malin inhibit PTG-mediated glycogen synthesis","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ae30c187-ef19-4e12-9ed0-23c411b25502","type":"EvidenceLine","dc:description":"The interaction was shown by three methods, yeast two hybrid, Pull-down, and immunoprecipitation.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d03c312e-6268-4ca2-aa41-77d232d5d8fd","type":"Finding","dc:description":"NHLRC1 is the only other gene that has been associated with Lafora disease. NHLRC1 encodes Malin, which physically binds to Laforin.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15930137","rdfs:label":"Laforin-Malin interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4},{"id":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f970ced6-0164-41ed-9e1f-1fb9f892bca6_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0a8d6d69-4652-49ec-84c8-a5f0ca40e1f6_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12019207","rdfs:label":"LD44","family":{"id":"https://genegraph.clinicalgenome.org/r/0a8d6d69-4652-49ec-84c8-a5f0ca40e1f6","type":"Family","rdfs:label":"LD44","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/fc00e39d-9ca7-49c4-8ff8-7c2f88ceee52","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12019207","rdfs:label":"LD44p","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":6,"detectionMethod":"","firstTestingMethod":"PCR","phenotypes":["obo:HP_0001250","obo:HP_0000726","obo:HP_0002361","obo:HP_0001251"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/8d4d30ae-539a-4f04-ada6-e1539de533ea_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12019207","allele":{"id":"https://genegraph.clinicalgenome.org/r/dd62f0d5-cd4c-4ec1-8de1-fdce1c30016a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145735426A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366188499"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0001250","obo:HP_0001251","obo:HP_0000726","obo:HP_0002361"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/fc00e39d-9ca7-49c4-8ff8-7c2f88ceee52"}},{"id":"https://genegraph.clinicalgenome.org/r/b41f6bf9-be67-4cde-bfa2-df1c3075c399_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"65","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/b41f6bf9-be67-4cde-bfa2-df1c3075c399","type":"Family","rdfs:label":"65","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/7efb3f1f-609c-4083-b0da-38be930558f3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"65p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents and proband ; later haplotype analysis was done as well with 7 markers.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0002123","obo:HP_0002344","obo:HP_0002353","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/ea798b38-8325-4ad3-9966-2806aeda2db0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":{"id":"https://genegraph.clinicalgenome.org/r/3984eb78-2059-4af6-b667-2e02500f79c3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NR_153398.2(EPM2A):n.116+661C>G (undefined)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366187942"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002353","obo:HP_0002123","obo:HP_0002344","obo:HP_0100318"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/7efb3f1f-609c-4083-b0da-38be930558f3"}},{"id":"https://genegraph.clinicalgenome.org/r/46313491-48ca-49fe-bc86-11e3ec247bf9_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","rdfs:label":"LD33","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/46313491-48ca-49fe-bc86-11e3ec247bf9","type":"Family","rdfs:label":"LD33","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/f1b0cfce-b601-44c8-a63b-1729ce7fde68","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","rdfs:label":"LD33p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Genotyping with microsatellite markers in the previously found Lafora critical region in 6q24 for all members and haplotypes were constructed. Exon 2 and 4 were sequenced.","firstTestingMethod":"Genotyping","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0100318","obo:HP_0002123","obo:HP_0002344","obo:HP_0002353"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/70b20145-03f2-4e89-9742-b47b751f194c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","allele":{"id":"https://genegraph.clinicalgenome.org/r/d96368da-40f9-452f-8516-e63e8f1ed6bb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005670.4(EPM2A):c.878A>T (p.Gln293Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA314502"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002353","obo:HP_0002123","obo:HP_0002344","obo:HP_0100318"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/f1b0cfce-b601-44c8-a63b-1729ce7fde68"}},{"id":"https://genegraph.clinicalgenome.org/r/66fec87c-cc73-4b1d-bc2b-68dcee469b14_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"4","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/66fec87c-cc73-4b1d-bc2b-68dcee469b14","type":"Family","rdfs:label":"4","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/fa148be0-0355-4d96-9f0d-968082f1ce40","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"4p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents and proband ; later haplotype analysis was done as well with 7 markers.","firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0100318","obo:HP_0002344","obo:HP_0002353","obo:HP_0002123"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/0143a333-c1d5-421f-b7b8-fd83b91e61c6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":{"id":"https://genegraph.clinicalgenome.org/r/1030032e-aa00-4ab8-812b-ba20b2a4cb45","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145735241G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366187926"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002353","obo:HP_0100318","obo:HP_0002344","obo:HP_0002123"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/fa148be0-0355-4d96-9f0d-968082f1ce40"}},{"id":"https://genegraph.clinicalgenome.org/r/250e811f-a47f-4114-9ddb-2432378a247e_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individual.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","rdfs:label":"LD100-4","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/250e811f-a47f-4114-9ddb-2432378a247e","type":"Family","rdfs:label":"LD100-4","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/0017012d-db9b-4a26-987c-0bdc272458c2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","rdfs:label":"LD100-4p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Genotyping with microsatellite markers in the previously found Lafora critical region in 6q24 for all members and haplotypes were constructed. Exon 2 and 4 were sequenced.","firstTestingMethod":"Genotyping","phenotypes":["obo:HP_0002123","obo:HP_0100318","obo:HP_0002353","obo:HP_0002344"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/4f6db703-2552-4614-91bc-abaa97483cda_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","allele":{"id":"https://genegraph.clinicalgenome.org/r/e8eb66db-f480-430a-8776-49ee811a0876","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145627613dup","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915940611"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002123","obo:HP_0002344","obo:HP_0002353","obo:HP_0100318"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/0017012d-db9b-4a26-987c-0bdc272458c2"}},{"id":"https://genegraph.clinicalgenome.org/r/5c67a11b-662c-4b09-a066-967397a0a7c0_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14722920","rdfs:label":"IA","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/5c67a11b-662c-4b09-a066-967397a0a7c0","type":"Family","rdfs:label":"IA","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/2f00cae7-6d1d-4d5a-ac5e-36b6ae5e2928","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14722920","rdfs:label":"IAp","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":14,"detectionMethod":"Sanger sequencing of exon 1-4 of EPM2A. The identified variants were also tested in parents to confirm that the variants were compound heterozygous. Separately, entire coding sequences of NHLRC1/EPM2B was sequenced to rule out contribution of this gene. The exon 4 was sequenced in 100 control individuals to rule out the c.950insT variant in the general population.","firstTestingMethod":"PCR","phenotypeFreeText":"EEG background was slow, with frequent paroxysmal generalized irregular spike-wave discharges.","phenotypes":["obo:HP_0002123","obo:HP_0002344","obo:HP_0002069","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/d34a6e71-188e-4203-aea1-32868cf0157d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/14722920","allele":[{"id":"https://genegraph.clinicalgenome.org/r/75088772-07c8-436a-a52c-46ab575e8be8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005670.4(EPM2A):c.953dup (p.Gln319fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252548"}},{"id":"https://genegraph.clinicalgenome.org/r/1f68a8b1-5ec0-42c6-98ae-a012b4e19fa7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145735342_145735456del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915940653"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG background was slow, with frequent paroxysmal generalized irregular spike-wave discharges.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0100318","obo:HP_0002069","obo:HP_0002123","obo:HP_0002344"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/2f00cae7-6d1d-4d5a-ac5e-36b6ae5e2928"}},{"id":"https://genegraph.clinicalgenome.org/r/d4b4afd7-863d-4bcb-abba-b991e4f5312e_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12560877","rdfs:label":"Ki","estimatedLodScore":0.12,"family":{"id":"https://genegraph.clinicalgenome.org/r/d4b4afd7-863d-4bcb-abba-b991e4f5312e","type":"Family","rdfs:label":"Ki","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/482c2b6c-1cd8-4cae-ad40-11ddf61bd21b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12560877","rdfs:label":"Kip","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":10,"detectionMethod":"Sanger sequencing of Exon 1-4. The variant was also confirmed by restriction enzyme length polymorphism.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"EEG showed a slowing of background activity and very frequent discharges of spikes, polyspikes, and generalized spike waves.","phenotypes":["obo:HP_0002123","obo:HP_0100318","obo:HP_0002069"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Other","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/a9243df3-bf91-4192-b0c6-7b242541be6c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/12560877","allele":[{"id":"https://genegraph.clinicalgenome.org/r/47385532-446f-4fec-82c1-78cc410d203d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145735275_145735276insG","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915940652"}},{"id":"https://genegraph.clinicalgenome.org/r/4ce02451-fea8-404e-a105-713fbc986eb6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145635404T>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366191423"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slowing of background activity and very frequent discharges of spikes, polyspikes, and generalized spike waves.","phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0100318","obo:HP_0002069","obo:HP_0002123"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/482c2b6c-1cd8-4cae-ad40-11ddf61bd21b"}},{"id":"https://genegraph.clinicalgenome.org/r/3235475d-befa-4452-8082-adb044db44e2_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"114","estimatedLodScore":0.37,"family":{"id":"https://genegraph.clinicalgenome.org/r/3235475d-befa-4452-8082-adb044db44e2","type":"Family","rdfs:label":"114","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/1c9f0de2-b736-44cc-9550-d02cab439565","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"114-2","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents, proband and healthy sister; later haplotype analysis was done as well with 7 markers.","firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0002344","obo:HP_0002123","obo:HP_0002353","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/9666fd27-a084-40fa-932a-72e97357395a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":{"id":"https://genegraph.clinicalgenome.org/r/1c43cba2-2416-4f3a-84b6-9678a9889798","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005670.4(EPM2A):c.335dup (p.Tyr112Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252545"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":3,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002123","obo:HP_0100318","obo:HP_0002344","obo:HP_0002353"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/1c9f0de2-b736-44cc-9550-d02cab439565"}},{"id":"https://genegraph.clinicalgenome.org/r/d6598844-36c9-472d-b479-bde7f55776d7_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"102","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/d6598844-36c9-472d-b479-bde7f55776d7","type":"Family","rdfs:label":"102","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/0dc95ba3-eaa7-41a9-b735-8a4b96bbb07a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"102p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents and proband ; later haplotype analysis was done as well with 7 markers.","firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0002353","obo:HP_0002123","obo:HP_0002344","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/1d4474ca-45de-4af4-9b3c-cad2c6af999c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":[{"id":"https://genegraph.clinicalgenome.org/r/0d2a9590-f493-428d-a184-baa52b8f689e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NR_153398.2(EPM2A):n.453T>A (undefined)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366190097"}},{"id":"https://genegraph.clinicalgenome.org/r/b903eb48-614c-4c34-a263-f7b1b30d090a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145735366_145735397del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915940612"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002344","obo:HP_0002123","obo:HP_0002353","obo:HP_0100318"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/0dc95ba3-eaa7-41a9-b735-8a4b96bbb07a"}},{"id":"https://genegraph.clinicalgenome.org/r/d5185a54-5a0f-4ff9-9bcf-bd8e5d53a46c_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","rdfs:label":"LD20","family":{"id":"https://genegraph.clinicalgenome.org/r/d5185a54-5a0f-4ff9-9bcf-bd8e5d53a46c","type":"Family","rdfs:label":"LD20","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/ff07790d-1478-4870-865e-a109b624a14c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","rdfs:label":"LD20p","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":13,"detectionMethod":"Sanger sequencing of exon 1 in EPM2A.","firstTestingMethod":"PCR","phenotypes":["obo:HP_0002069","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/8ac3acd6-a50b-4b16-b3b9-70ba4b424cc4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","allele":{"id":"https://genegraph.clinicalgenome.org/r/bf36e4f1-547b-4541-bfb5-af5e869a68d8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005670.4(EPM2A):c.163C>T (p.Gln55Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16618251"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002069","obo:HP_0100318"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/ff07790d-1478-4870-865e-a109b624a14c"}},{"id":"https://genegraph.clinicalgenome.org/r/77cf8af9-660c-4dc1-b2ce-8532347cc339_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"119","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/77cf8af9-660c-4dc1-b2ce-8532347cc339","type":"Family","rdfs:label":"119","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/97497bcd-8afa-4dbe-b4e4-bb235db4d3a7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"119p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents and proband; later haplotype analysis was done as well with 7 markers.","firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0100318","obo:HP_0002123","obo:HP_0002344","obo:HP_0002353"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/7f55f043-91e7-4d85-9e2f-e998d89074b6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":[{"id":"https://genegraph.clinicalgenome.org/r/70c7053d-3fef-4f08-8d29-c9e5dd36f16d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NR_153398.2(EPM2A):n.292-7552G>A (undefined)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366190778"}},{"id":"https://genegraph.clinicalgenome.org/r/680f59cf-397a-439b-b90e-c9783207a3b8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005670.4(EPM2A):c.759delinsCATGCA (p.Ala254fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA645369324"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0100318","obo:HP_0002344","obo:HP_0002353","obo:HP_0002123"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/97497bcd-8afa-4dbe-b4e4-bb235db4d3a7"}},{"id":"https://genegraph.clinicalgenome.org/r/f0c3c510-67d9-426f-b91f-bf83821a95b9_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","rdfs:label":"MB","family":{"id":"https://genegraph.clinicalgenome.org/r/f0c3c510-67d9-426f-b91f-bf83821a95b9","type":"Family","rdfs:label":"MB","ethnicity":{"id":"cg:UnknownEthnicity"},"member":{"id":"https://genegraph.clinicalgenome.org/r/213d3f15-82ac-4ac9-8ba8-57de8efa4c84","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","rdfs:label":"MBp","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":14,"detectionMethod":"Sanger sequencing of the exon 1 of EPM2A.","ethnicity":{"id":"cg:UnknownEthnicity"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0002123","obo:HP_0002069","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/3b3f9cbb-20a9-46b0-9be9-df00143f4487_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","allele":{"id":"https://genegraph.clinicalgenome.org/r/1a477ba0-5d36-49cb-ba0b-a9d90ea61a4a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145735265del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915940651"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002123","obo:HP_0100318","obo:HP_0002069"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/213d3f15-82ac-4ac9-8ba8-57de8efa4c84"}},{"id":"https://genegraph.clinicalgenome.org/r/b5213546-532c-4160-bb08-ded2ac24dc7b_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","rdfs:label":"AI","family":{"id":"https://genegraph.clinicalgenome.org/r/b5213546-532c-4160-bb08-ded2ac24dc7b","type":"Family","rdfs:label":"AI","ethnicity":{"id":"cg:NotHispanicOrLatino"},"member":{"id":"https://genegraph.clinicalgenome.org/r/dd254423-4b5d-4630-b937-9c70b7415559","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","rdfs:label":"AIp","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":15,"detectionMethod":"Sanger sequencing of the exon 1 of EPM2A.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"PCR","phenotypes":["obo:HP_0002367","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/298ce158-8c92-4088-bc2d-f61a63390203_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","allele":{"id":"https://genegraph.clinicalgenome.org/r/b8f78184-3e34-467d-b126-ca112cc421ac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145735320C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366188101"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0100318","obo:HP_0002367"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/dd254423-4b5d-4630-b937-9c70b7415559"}},{"id":"https://genegraph.clinicalgenome.org/r/3410ae8c-cc4e-46cc-9fbb-af0c7c6447d1_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"12","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/3410ae8c-cc4e-46cc-9fbb-af0c7c6447d1","type":"Family","rdfs:label":"12","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/687151ed-39ca-4342-a0b2-f9535f655157","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"12p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents and proband; later haplotype analysis was done as well with 7 markers.","firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0002344","obo:HP_0002353","obo:HP_0002123","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/548a51cc-9bd2-4cfb-9560-1c3bed63fe3e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":[{"id":"https://genegraph.clinicalgenome.org/r/c92c570b-8038-4aa6-9517-80e6aa94673b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005670.4(EPM2A):c.721C>T (p.Arg241Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA314500"}},{"id":"https://genegraph.clinicalgenome.org/r/e17b521a-4d7e-45aa-93fb-95c325de638a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NR_153398.2(EPM2A):n.292-7689C>T (undefined)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA149184184"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002123","obo:HP_0002353","obo:HP_0002344","obo:HP_0100318"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/687151ed-39ca-4342-a0b2-f9535f655157"}},{"id":"https://genegraph.clinicalgenome.org/r/bbf2115d-0b11-4b0a-8f63-0e35615ddfb6_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","rdfs:label":"I22","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/bbf2115d-0b11-4b0a-8f63-0e35615ddfb6","type":"Family","rdfs:label":"I22","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/d61e4919-eed1-4ff1-9f85-7135ea855176","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","rdfs:label":"I22p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"Genotyping with microsatellite markers in the previously found Lafora critical region in 6q24 for all members and haplotypes were constructed. Exon 2 and 4 were sequenced.","firstTestingMethod":"Genotyping","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0002123","obo:HP_0002353","obo:HP_0002344","obo:HP_0100318"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/41b29dd9-69a2-4be1-a387-ea4e57687ca8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9771710","allele":{"id":"https://genegraph.clinicalgenome.org/r/c0cb92fd-c3c3-470f-8b2a-41f579a54708","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145686186C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA366188412"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0100318","obo:HP_0002344","obo:HP_0002353","obo:HP_0002123"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/d61e4919-eed1-4ff1-9f85-7135ea855176"}},{"id":"https://genegraph.clinicalgenome.org/r/246ad379-a650-483f-a783-dcbf9b090d8b_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","rdfs:label":"LD52","family":{"id":"https://genegraph.clinicalgenome.org/r/246ad379-a650-483f-a783-dcbf9b090d8b","type":"Family","rdfs:label":"LD52","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/553b6bc1-01a3-4e8f-9333-98e4eb3ea522","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","rdfs:label":"LD52p","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":13,"detectionMethod":"Sanger sequencing of exon 1 of EPM2A.","firstTestingMethod":"PCR","phenotypes":["obo:HP_0100318","obo:HP_0001250"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/8b7e1d3f-fbcf-4d22-92e7-c749ede8dc43_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10932264","allele":{"id":"https://genegraph.clinicalgenome.org/r/2fdfa976-92dd-4a9d-b5a3-2e270013acf0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005670.4(EPM2A):c.94T>G (p.Trp32Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252549"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"phenotypeFreeText":"","phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0001250","obo:HP_0100318"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/553b6bc1-01a3-4e8f-9333-98e4eb3ea522"}},{"id":"https://genegraph.clinicalgenome.org/r/326c102f-50db-47da-839f-96dae3de3635_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"110","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/326c102f-50db-47da-839f-96dae3de3635","type":"Family","rdfs:label":"110","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/f14646f2-fb4f-4e6b-a9bd-43fa9dc6307b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"110p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents and proband ; later haplotype analysis was done as well with 7 markers.","firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0002344","obo:HP_0002123","obo:HP_0100318","obo:HP_0002353"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/fc0a4ba7-0078-4946-b0f2-b06c0ca488d2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":{"id":"https://genegraph.clinicalgenome.org/r/d3807d6f-d699-4245-a056-157e6a6c1a21","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000006.12:g.145735226_145735232del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA915940627"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0100318","obo:HP_0002353","obo:HP_0002123","obo:HP_0002344"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/f14646f2-fb4f-4e6b-a9bd-43fa9dc6307b"}},{"id":"https://genegraph.clinicalgenome.org/r/7bb26afc-a525-4217-a070-6678c1aabc13_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"5","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/7bb26afc-a525-4217-a070-6678c1aabc13","type":"Family","rdfs:label":"5","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/d8eb8bb3-3223-4acb-adc9-b3f87059445d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"5p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents and proband ; later haplotype analysis was done as well with 7 markers.","firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0002353","obo:HP_0100318","obo:HP_0002344","obo:HP_0002123"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/e57aa6af-0e9f-4e2c-9cf6-b6aaeba07c56_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":{"id":"https://genegraph.clinicalgenome.org/r/0aae74b1-48e8-47c9-abee-ee441db2231c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_005670.4(EPM2A):c.322C>T (p.Arg108Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA252543"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002353","obo:HP_0002123","obo:HP_0002344","obo:HP_0100318"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/d8eb8bb3-3223-4acb-adc9-b3f87059445d"}},{"id":"https://genegraph.clinicalgenome.org/r/b3fef0b3-8111-4adb-8f30-48a6af87aa6c_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough affected individuals.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"113","estimatedLodScore":0.25,"family":{"id":"https://genegraph.clinicalgenome.org/r/b3fef0b3-8111-4adb-8f30-48a6af87aa6c","type":"Family","rdfs:label":"113","ethnicity":{"id":"https://genegraph.clinicalgenome.org/r/"},"member":{"id":"https://genegraph.clinicalgenome.org/r/4fe7838d-4075-4b24-8740-1bfc575f79cb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","rdfs:label":"113p","ageType":"https://genegraph.clinicalgenome.org/r/","ageUnit":"https://genegraph.clinicalgenome.org/r/","detectionMethod":"SSCP in exon 1-4, followed by SSCP and Sanger sequencing of parents and proband ; later haplotype analysis was done as well with 7 markers.","firstTestingMethod":"SSCP","phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypes":["obo:HP_0100318","obo:HP_0002353","obo:HP_0002123","obo:HP_0002344"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/181f77b6-fc33-47ff-a60e-c76f1dfba7b0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11175283","allele":{"id":"https://genegraph.clinicalgenome.org/r/c92c570b-8038-4aa6-9517-80e6aa94673b"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"}}}},"meetsInclusionCriteria":false,"phenotypeFreeText":"EEG showed a slow background with polyspike wave complexes.","phenotypeNegativeAlleleNegative":2,"phenotypePositiveAllelePositive":1,"phenotypes":["obo:HP_0002353","obo:HP_0100318","obo:HP_0002123","obo:HP_0002344"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/4fe7838d-4075-4b24-8740-1bfc575f79cb"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/ea798b38-8325-4ad3-9966-2806aeda2db0_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The point was upgraded because the variant has been functionally studied.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7efb3f1f-609c-4083-b0da-38be930558f3"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9666fd27-a084-40fa-932a-72e97357395a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1c9f0de2-b736-44cc-9550-d02cab439565"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/298ce158-8c92-4088-bc2d-f61a63390203_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Only the exon 1 of EPM2A was tested. This is a homozygous nonsense variant. It is not clear whether parents were tested. No functional studies are done. Points were reduced because it is not clear whether the parents were tested.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dd254423-4b5d-4630-b937-9c70b7415559"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/e57aa6af-0e9f-4e2c-9cf6-b6aaeba07c56_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The point was upgraded, because the variant has been studied functionally.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d8eb8bb3-3223-4acb-adc9-b3f87059445d"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/d34a6e71-188e-4203-aea1-32868cf0157d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Both EPM2A and NHLRC1 were tested in the patient. Parents were tested to confirm that the patient is compound heterozygous for the variants. For the isoform A specific variant, functional study was done and it showed the reduction in phosphatase activity and inability to make a heterodimer with the isoform B. The other variant is expected to cause a nonsense-,mediated decay of the transcript. Lafora bodies were detected in muscle biopsy and skin biopsy. Since Lafora bodies were documented, parents were tested, and functional study was done on one of the variants, the point was upgraded to 2.5.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2f00cae7-6d1d-4d5a-ac5e-36b6ae5e2928"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/181f77b6-fc33-47ff-a60e-c76f1dfba7b0_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The point has been upgraded, because the variant has been studied functionally.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4fe7838d-4075-4b24-8740-1bfc575f79cb"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7f55f043-91e7-4d85-9e2f-e998d89074b6_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Full points were given because the missense variant has been functionally studied.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/97497bcd-8afa-4dbe-b4e4-bb235db4d3a7"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/41b29dd9-69a2-4be1-a387-ea4e57687ca8_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d61e4919-eed1-4ff1-9f85-7135ea855176"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/a9243df3-bf91-4192-b0c6-7b242541be6c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Proband and mother were tested. Father was not tested, because he refused the test. Mother had c.559A>G; T187A but not c.223_224insC; p.Gly75Alafs*33. So, it is not clear whether c.223_224insC; p.Gly75Alafs*33 was from father or de novo. So, the variants are presumably compound heterozygous. No functional studies were done. Neither variants are present in gnomAD or Clinvar. Only EPM2A was tested. Lafora bodies in the sweat gland duct cells were shown in a picture.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/482c2b6c-1cd8-4cae-ad40-11ddf61bd21b"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0143a333-c1d5-421f-b7b8-fd83b91e61c6_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fa148be0-0355-4d96-9f0d-968082f1ce40"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/70b20145-03f2-4e89-9742-b47b751f194c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Although only two exons were studied in one gene, functional studies were done on the variant.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f1b0cfce-b601-44c8-a63b-1729ce7fde68"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3b3f9cbb-20a9-46b0-9be9-df00143f4487_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Only the exon 1 of EPM2A was tested. This is a homozygous truncating variant in exon 1. It is not clear whether the parents were tested. No functional studies were done. Points were reduced because it is not clear whether the parents were tested.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/213d3f15-82ac-4ac9-8ba8-57de8efa4c84"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4f6db703-2552-4614-91bc-abaa97483cda_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Only two exons in EPM2A was studied. No functional studies done","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0017012d-db9b-4a26-987c-0bdc272458c2"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8ac3acd6-a50b-4b16-b3b9-70ba4b424cc4_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Only the exon 1 of EPM2A was tested. This is a homozygous nonsense variant. It is not clear whether parents were tested. No functional studies are done. Points were reduced because it is not clear whether the parents were tested.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ff07790d-1478-4870-865e-a109b624a14c"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/548a51cc-9bd2-4cfb-9560-1c3bed63fe3e_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Although only EPM2A has been tested, one of the variant is a well-documented Spanish founder variant with multiple pathogenic entries in Clinvar. Both variants have been tested functionally. Please note that c.721C>T (p.Arg241Ter) is in the last coding exon, and therefore, theoretically it is not expected to cause nonsense-mediated decay of the transcripts. However, primary fibroblast cells derived from homozygous p.Arg241* patient had undetectable level of Laforin protein, and reduced level of EPM2A transcript (30041081), suggesting that nonsense-mediated decay of the transcript may occur to this variant. Points were upgraded to full due to functional studies.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/687151ed-39ca-4342-a0b2-f9535f655157"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/8b7e1d3f-fbcf-4d22-92e7-c749ede8dc43_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Only EPM2A was tested. Only exon 1 was tested. It's not clear whether the parents were tested. Functional studies showed the variant has functional effects such as change in subcellular localization, stability, phosphatase activity, and association with glycogen. This is a homozygous missense variant. Points were reduced because it is not clear whether the parents were tested.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/553b6bc1-01a3-4e8f-9333-98e4eb3ea522"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/8d4d30ae-539a-4f04-ada6-e1539de533ea_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The variant is not in gnomAD. It is not clear whether the parents were tested. Glycogen and Lafora body binding by the carbohydrate binding domain was not affected 14706656. The EGFP-tagged variant protein was not detected when expressed in HeLa cells 12019207. This result may be a positive functional study, but there is also a possibility that their construct failed. Taken together, there is not enough evidence of a positive functional effect. Furthermore, lafora bodies were not studied in this patient.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fc00e39d-9ca7-49c4-8ff8-7c2f88ceee52"}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/1d4474ca-45de-4af4-9b3c-cad2c6af999c_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0dc95ba3-eaa7-41a9-b735-8a4b96bbb07a"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/fc0a4ba7-0078-4946-b0f2-b06c0ca488d2_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f14646f2-fb4f-4e6b-a9bd-43fa9dc6307b"}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":682,"specifiedBy":"GeneValidityCriteria7","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/k96x0Cgv2Z8","type":"GeneValidityProposition","disease":"obo:MONDO_0009697","gene":"hgnc:3413","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_f970ced6-0164-41ed-9e1f-1fb9f892bca6-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}